Secretion of the Notch-1 Aβ-like Peptide during Notch Signaling
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The canonical pathway of Notch signaling is mediated by regulated intramembrane proteolysis (RIP). In the pathway, ligand binding results in sequential proteolysis of the Notch receptor, and presenilin (PS)-dependent intramembrane proteolysis at the interface between the membrane and cytosol liberates the Notch-1 intracellular domain (NICD), a transcription modifier. Because the degradation of the Notch-1 transmembrane domain is thought to require an additional cleavage near the middle of the transmembrane domain, extracellular small peptides (Notch-1 Abeta-like peptide (Nbeta)) should be produced. Here we showed that Nbeta species are indeed secreted during the process of Notch signaling. We identified mainly two distinct molecular species of novel Nbeta, Nbeta21 and C-terminally elongated Nbeta25, which were produced in an approximately 5:1 ratio. This process is reminiscent of the production of Alzheimer disease-associated Abeta. PS pathogenic mutants increased the production of the longer species of Abeta (Abeta42) from beta-amyloid protein precursor. We revealed that several Alzheimer disease mutants also cause a parallel increase in the secretion of the longer form of Nbeta. Strikingly, chemicals that modify the Abeta42 level caused parallel changes in the Nbeta25 level. These results demonstrated that the characteristics of C-terminal elongation of Nbeta and Abeta are almost identical. In addition, because many other type 1 membrane-bound receptors release intracellular domains by PS-dependent intramembrane proteolysis, we suspect that the release of Abeta- or Nbeta-like peptides is a common feature of the proteolysis during RIP signaling. We anticipate that this study will open the door to searches for markers of RIP signaling and surrogate markers for Abeta42 production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Cited by
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Concise Review: Notch Signaling in Stem Cell Systems
Chiba, S. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0661 · Cited by 399
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 280
Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions
Szaruga, M., Munteanu, B., Lismont, S., Veugelen, S., Horré, K., Mercken, M., Saido, T. C., Ryan, N. S., De Vos, T., Savvides, S. N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.004 · Cited by 248
The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble
Wolfe, M. S. (2006) · Biochemistry · doi:10.1021/bi060799c · Cited by 161
γ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs
Oehlrich, D., Berthelot, D. J.-C., & Gijsen, H. J. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101168r · Cited by 161
Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123
“…way to the effect of GSMs. Long Ab-like Peptides Other Than Ab Are Also Substrates of PS/g-Secretase Ab-like peptides (Okochi et al., 2002), secreted by a process similar to that for Ab secretion, include mNotch-1-derived Nb (Okochi et al., 2006) and APLP1-derived APL1b (Yanagida et al., 2009).”
BackgroundSelf-citationQuintero-Monzon, O., Martin, M. M., Fernandez, M. A., Cappello, C. A., Krzysiak, A. J., Osenkowski, P., & Wolfe, M. S. (2011) · Biochemistry · doi:10.1021/bi2007146 · Cited by 118
The ADAMs family: Coordinators of nervous system development, plasticity and repair
Yang, P., Baker, K. A., & Hagg, T. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.05.001 · Cited by 116
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Li, S.-H., Gao, P., Wang, L.-T., Yan, Y.-H., Xia, Y., Song, J., Li, H.-Y., & Yang, J.-X. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00340 · Cited by 46
Hahn, S., Brüning, T., Ness, J., Czirr, E., Baches, S., Gijsen, H., Korth, C., Pietrzik, C. U., Bulic, B., & Weggen, S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07118.x · Cited by 42
Michellod, M.-A., & Randsholt, N. B. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.10.060 · Cited by 18
Metadata
- Authors
- Okochi, M., Fukumori, A., Jiang, J., Itoh, N., Kimura, R., Steiner, H., Haass, C., Tagami, S., & Takeda, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 281
- Issue
- 12
- Pages
- 7890-7898
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1981293839
- Cited by
- 100
- References
- 3
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.